Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
- Conditions
- unresectable stage III NSCLC (Non–small-cell lung cancer)
- Registration Number
- 2024-513948-28-00
- Brief Summary
Primary objective
To evaluate the safety and tolerability of either conventionally fractionated (CON-group) or hypofractionated (HYPO-group) thoracic radiotherapy in combination with durvalumab.
Primary efficacy objective
To investigate the efficacies of either mode of fractionation of radiotherapy in combination with durvalumab with respect to the response rates in patients with unresectable stage III NSCLC, who are not suitable for chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruitment ended
- Sex
- Not specified
- Target Recruitment
- 57
Fully-informed written consent and locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
At least one measurable site of disease as defined by RECIST 1.1 criteria.
Adequate bone marrow and renal function including the following: / - Hemoglobin ≥ 9.0 g/dL / - absolute neutrophil count ≥ 1.0 x 109 /L / - platelets ≥75x 109 /L / - Calculated creatinine clearance ≥30 mL/min as determined by the Cockcroft-Gault equation
Adequate hepatic function (with stenting for any obstruction, if required) including the following: - Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) / - AST (SGOT) / ALT (SGPT) ≤ 2.5x institutional ULN
Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: - Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). / - Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiationinduced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
Age ≥ 18 years.
Histologically documented diagnosis of unresectable stage III NSCLC
Non-feasibility of sequential chemo-/radiotherapy as determined by the site’s multi-disciplinary tumor board; if there is no tumor board, then this decision will be made by the investigator in consultation with a radiation oncologist, if the investigator is not a radiation oncologist; or by the investigator in consultation with an oncologist, if the investigator is not an oncologist.
Fulfills at least one of the following criteria: - Performance status (PS) 2 (ECOG scale) / - ECOG 1 and CCI ≥ 1 / - Age ≥ 70 years
Must have a life expectancy of at least 12 weeks.
FEV1 ≥ 40% (Best/Soll)
DLCO or DLCO/VA (Hb-corrected, if available) ≥ 40% (Best/Soll)
FVC or VC ≥ 70% (Best/Soll)
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the followup period of an interventional study.
Active, uncontrolled inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]. Patients in stable remission for more than 1 year may be included.
Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, interstitial lung disease, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
History of another primary malignancy except for: - Malignancy treated with curative intent and with no known active disease ≥ 3 years before the first dose of IMP and of low potential risk for recurrence / - Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease / - Adequately treated carcinoma in situ without evidence of disease
History of leptomeningeal carcinomatosis
History of active primary immunodeficiency
History of allogenic organ or tissue transplantation.
Clinical diagnosis of active tuberculosis.
Positive testing for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Positive testing for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: - Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection) / - Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent / - Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment.
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab monotherapy.
Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product.
Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study.
Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
Prior immunotherapy or use of other investigational agents, including prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti- Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T-lymphocyte associated antigen-4 (anti-CTLA-4) antibody, therapeutic cancer vaccines.
History or current radiology suggestive of interstitial lung disease.
Oxygen-dependent medical condition.
Any concurrent chemotherapy, investigational product (IMP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (eg, hormone replacement therapy) is acceptable.
Prior thoracic radiotherapy within the past 5 years before the first dose of study drug.
Major surgery (as defined by the Investigator) within 4 weeks prior to enrollment into the study; patients must have recovered from effects of any major surgery. Note: Local non-major surgery for palliative intent is acceptable.
Active or prior documented autoimmune or inflammatory disorders (except inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]; including diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener’s syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: - Patients with vitiligo or alopecia / - Patients with hypothyroidism (e.g., ollowing Hashimoto’s disease) stable on hormone replacement / - Any chronic skin condition that does not require systemic therapy / - Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Endpoint: Toxicity, defined by the occurence of treatment-related pneumonitis grade ≥ 3 Primary Endpoint: Toxicity, defined by the occurence of treatment-related pneumonitis grade ≥ 3
Primary Efficacy Endpoint: Objective response according to RECIST 1.1 criteria Primary Efficacy Endpoint: Objective response according to RECIST 1.1 criteria
- Secondary Outcome Measures
Name Time Method Occurence of treatment-related AEs and SAEs according to CTCAE V5.0 Occurence of treatment-related AEs and SAEs according to CTCAE V5.0
Abnormal values of laboratory parameters Abnormal values of laboratory parameters
PFS according to RECIST 1.1 PFS according to RECIST 1.1
Duration of Clinical Benefit (Duration of CR, PR, SD) according to RECIST 1.1 Duration of Clinical Benefit (Duration of CR, PR, SD) according to RECIST 1.1
MFS MFS
OS OS
QoL (FACT-L) QoL (FACT-L)
Descriptive sub-group analyses of efficacy in relation to PD-L1 expression levels (<°1% vs ≥°1%) Descriptive sub-group analyses of efficacy in relation to PD-L1 expression levels (<°1% vs ≥°1%)
Trial Locations
- Locations (19)
Kliniken Maria Hilf GmbH Moenchengladbach
🇩🇪Moenchengladbach, Germany
Medizinische Hochschule Hannover
🇩🇪Hanover, Germany
Kliniken der Stadt Koeln gGmbH
🇩🇪Cologne, Germany
Universitaetsklinikum Frankfurt AöR
🇩🇪Frankfurt Am Main, Germany
Pi.Tri Studien GmbH
🇩🇪Offenburg, Germany
Universitaetsklinikum Mannheim GmbH
🇩🇪Mannheim, Germany
Sana Klinikum Offenbach GmbH
🇩🇪Offenbach Am Main, Germany
SLK-Kliniken Heilbronn GmbH
🇩🇪Loewenstein, Germany
Thoraxklinik Heidelberg gGmbH
🇩🇪Heidelberg, Germany
DRK Kliniken Berlin-Mitte
🇩🇪Berlin, Germany
Scroll for more (9 remaining)Kliniken Maria Hilf GmbH Moenchengladbach🇩🇪Moenchengladbach, GermanyUrsula NestleSite contact+4921618921801ursula.nestle@mariahilf.de